

3798 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

one or more conferences with representatives of the drug industry, pharmacy, clinical medicine, and consumer groups to consider--

- (a) Provision of incentives to the drug industry to invest more research effort in products representing significant improvements to therapy and less in duplicative, noncontributory drug products and combinations.
- (b) Development of a registration and licensing system under which no drug product would be permitted in interstate commerce unless produced under quality control standards set by the Secretary of Health, Education, and Welfare.
- (c) Limitation of free drug samples to those specifically requested by prescribers, by industry agreement or legislation.
- (d) Development of more effective methods for ascertaining actual acquisition costs of prescription drugs.